Motif Bio Announces FDA Acceptance of New Drug Application with Priority Review for Iclaprim for Treatment of Acute Bacterial Skin and Skin Structure Infections

Stock Information for Motif Bio plc

Loading

Please wait while we load your information from QuoteMedia.